The Application of microRNAs in Biomaterial Scaffold-Based Therapies for Bone Tissue Engineering
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim..
In recent years, the application of microRNAs (miRNAs) or anti-microRNAs (anti-miRNAs) that can induce expression of the runt-related transcription factor 2 (RUNX2), a master regulator of osteogenesis, has been investigated as a promising alternative bone tissue engineering strategy. In this review, biomaterial scaffold-based applications that have been used to deliver cells expressing miRNAs or anti-miRNAs that induce expression of RUNX2 for bone tissue engineering are discussed. An overview of the components of the scaffold-based therapies including the miRNAs/anti-miRNAs, cell types, gene delivery vectors, and scaffolds that have been applied are provided. To date, there have been nine miRNAs/anti-miRNAs (i.e., miRNA-26a, anti-miRNA-31, anti-miRNA-34a, miRNA-135, anti-miRNA-138, anti-miRNA-146a, miRNA-148b, anti-miRNA-221, and anti-miRNA-335) that have been incorporated into scaffold-based bone tissue engineering applications and investigated in an in vivo bone critical-sized defect model. For all of the biomaterial scaffold-based miRNA therapies that have been developed thus far, cells that are transfected or transduced with the miRNA/anti-miRNA are loaded into the scaffolds and implanted at the site of interest instead of locally delivering the miRNA/anti-miRNAs directly from the scaffolds. Thus, future work may focus on developing biomaterial scaffolds to deliver miRNAs or anti-miRNAs into cells in vivo.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Biotechnology journal - 14(2019), 10 vom: 09. Okt., Seite e1900084 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arriaga, Marco A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomaterials |
|---|
| Anmerkungen: |
Date Completed 10.02.2020 Date Revised 10.02.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/biot.201900084 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM297834363 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM297834363 | ||
| 003 | DE-627 | ||
| 005 | 20231225092842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/biot.201900084 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0992.xml |
| 035 | |a (DE-627)NLM297834363 | ||
| 035 | |a (NLM)31166084 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arriaga, Marco A |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Application of microRNAs in Biomaterial Scaffold-Based Therapies for Bone Tissue Engineering |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2020 | ||
| 500 | |a Date Revised 10.02.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. | ||
| 520 | |a In recent years, the application of microRNAs (miRNAs) or anti-microRNAs (anti-miRNAs) that can induce expression of the runt-related transcription factor 2 (RUNX2), a master regulator of osteogenesis, has been investigated as a promising alternative bone tissue engineering strategy. In this review, biomaterial scaffold-based applications that have been used to deliver cells expressing miRNAs or anti-miRNAs that induce expression of RUNX2 for bone tissue engineering are discussed. An overview of the components of the scaffold-based therapies including the miRNAs/anti-miRNAs, cell types, gene delivery vectors, and scaffolds that have been applied are provided. To date, there have been nine miRNAs/anti-miRNAs (i.e., miRNA-26a, anti-miRNA-31, anti-miRNA-34a, miRNA-135, anti-miRNA-138, anti-miRNA-146a, miRNA-148b, anti-miRNA-221, and anti-miRNA-335) that have been incorporated into scaffold-based bone tissue engineering applications and investigated in an in vivo bone critical-sized defect model. For all of the biomaterial scaffold-based miRNA therapies that have been developed thus far, cells that are transfected or transduced with the miRNA/anti-miRNA are loaded into the scaffolds and implanted at the site of interest instead of locally delivering the miRNA/anti-miRNAs directly from the scaffolds. Thus, future work may focus on developing biomaterial scaffolds to deliver miRNAs or anti-miRNAs into cells in vivo | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a biomaterials | |
| 650 | 4 | |a bone tissue engineering | |
| 650 | 4 | |a gene therapy | |
| 650 | 4 | |a microRNAs | |
| 650 | 4 | |a scaffolds | |
| 650 | 7 | |a Core Binding Factor Alpha 1 Subunit |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a RUNX2 protein, human |2 NLM | |
| 700 | 1 | |a Ding, May-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Gutierrez, Astrid S |e verfasserin |4 aut | |
| 700 | 1 | |a Chew, Sue Anne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biotechnology journal |d 2006 |g 14(2019), 10 vom: 09. Okt., Seite e1900084 |w (DE-627)NLM164618910 |x 1860-7314 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2019 |g number:10 |g day:09 |g month:10 |g pages:e1900084 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/biot.201900084 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2019 |e 10 |b 09 |c 10 |h e1900084 | ||